Yes,
we’ve done
May 2011 Volume 18 No.1
Dear Zydans,
A lot has been said about a ‘winning habit’ – it creates a rhythm that
keeps building a momentum and lifts our spirits. I also believe that
alongwith this habit comes a mindset, an attitude. It creates buoyancy
that becomes a springboard for future successes.
When we look back at our journey over the years, this theory does
seem to get reinforced. Starting from 1995, we have boldly gone
forth and set ourselves goals – specific targets without
any ambiguities. Each time, we backed up our plans
with action, walking the talk every inch of the way.
From a turnover of Rs.1000 by the year 2000,
$ 400 million by 2006-07 and now the Healthy
Billion target of crossing sales of over $ 1 bn in
2011, our winning habit continues. Every step
of the way, we have evolved and in the process
have transformed ourselves.
In 1995, we were an India-focussed company.
A decade later we had confidently made our
entry into the global generics market and were
expanding our global footprint. And here we are
today, poised to move on Beyond the Billion – with
new goals and new aspirations.
At the start of the HB year we looked at the colours of celebration
and ended the year by saying there would be a billion smiles across
the Zydus world. Indeed, the colours of celebration that have brought
these billion smiles are a result of our collective efforts. Across USA,
Europe, Japan, Latin America, Africa and Asia the smiles were the
confidence of a winner.
illion
sB
du
ow
Zy
T
a rds thy
the Heal
it !
There are more than 12500 of us building a new future with our
ideas and actions. This is the collective energy that we can unleash
to realize our dreams. The key lies in doing this as efficiently as
possible. Our winning habit comes from harnessing our collective
power into a single-minded pursuit of our goal.
For the last four years we’ve stayed focused on the Healthy
Billion goal. As we go about our next goal to post sales
of over $ 3 bn by 2015, there will be new challenges
that we will have to overcome, new vistas that we
will have to explore. But that is exactly what
makes each journey interesting.
When we look back, we see a luminous path.
This has been illumined by our achievements
along the way. As a new path opens up, let us
set it aglow with our actions. Let our winning
ways make it brighter than before.
P. R. Joshi
What’s Inside
New beginnings pg 2-3 International beat pg 5-9 India updates pg 12-16
News updates from Moraiya, ZRC, PTC,
Zydus Wellness and ZAHL pg 17-19
The learning wheel pg 20-22
Our group enters the billion dollar league
It was a unique moment in our corporate history
– a moment that we had been planning on for the
last 4 years. On 31st March 2011, it was declared
that we had achieved the ‘Healthy Billion’. It’s
truly a moment of pride for all Zydans as it is the
collective efforts of all Zydans that has made this
feat possible.
We now take the next big leap forward, stepping
beyond the billion to achieve sales of $ 3 billion by
2015 and become a research driven pharma major
by 2020.
2
A new beginning : Bayer Zydus Pharma

One of our models for growth has been to forge win-win partnerships with global pharma majors. We have successfully collaborated with
Nycomed to create Zydus Nycomed and with Hospira to create Zydus Hospira. Both joint ventures have helped their respective partners scale
higher peaks in terms of growth and profitability.
Recently, our group joined hands with Bayer Healthcare to create a new 50: 50 joint venture company: Bayer Zydus Pharma to market pharma
products in India. To create this joint venture Bayer HealthCare has contributed its existing pharmaceutical division comprising its sales and
marketing business in India to the new company. Our group has contributed the women’s healthcare products of Evona and the diagnostic
imaging business. In the coming years, the new JV also intends to focus on the sales and marketing of the future patented pipeline of Bayer’s
pharmaceutical products. Bayer Zydus Pharma will operate in key segments of the Indian pharmaceuticals market with a focus on: women’s
healthcare, metabolic disorders, diagnostic imaging, cardiovascular diseases, anti-diabetic treatments and oncology.
Seen here are our Chairman and Managing Director, Mr. Pankaj R. Patel and Mr. Stephen Gerlich, Group Head, Bayer Group of Companies
at the signing of the agreement of the JV. The teams from Zydus and Bayer are seen posing for a photograph after the JV signing ceremony.

Our IND application of ZYGK1 for treating diabetes receives USFDA approval
Our group has received an approval from the USFDA for the IND application of ZYGK1. Designed and developed at
the Zydus Research Centre, the NME is a potent and orally administered small molecule glucokinase activator.
Glucokinase (GK) is the enzyme that acts as a glucose sensor in the pancreas and regulates glucose metabolism
in the liver. When, circulating glucose levels rise above a certain threshold, the glucokinase enzyme enhances
insulin release from pancreas and decreases glucose production in liver. In normal individuals, the pancreas
secrete insulin in response to increased levels of glucose in the blood. In patients with Type 2 diabetes, there is a
reduction of GK activity in the pancreas and the liver.
In multiple preclinical models of Type 2 diabetes, ZYGK1 was found to be effective in controlling both fasting
and non-fasting blood glucose. ZYGK1 showed very good safety profile in preclinical studies. Activating GK
with small molecules such as ZYGK1 lower blood glucose levels by enhancing the ability of the pancreas to
sense glucose, which leads to increased insulin production. Simultaneously, glucokinase activators increase the
net uptake of blood glucose by the liver. Glucokinase activators, such as ZYGK1, represent a promising new
class of drugs for the treatment of Type 2 diabetes.

Setting up a new facility dedicated to Quality

In keeping with our expansion plans over the next five years, a new building
dedicated to Quality Control (QC) operations is being set up at Moraiya,
Ahmedabad. The foundation stone laying ceremony was performed by
Mr. M. K. Patel, Managing Director, Zydus Technologies and Mr. R. R.
Tuljapurkar, President, Corporate QA, on 9th April 2011. A four storeyed,
modern structure spread over an area of more than 10000 sq.mtrs., the new
facility will offer all quality related services such as QC and Microbiology,
Quality Assurance and Validation,
Stability and Analytical Method
Validation etc.
The building which will have a unique
pyramid structure at the entrance is
expected to be ready next year.
 3

The Economic Times Awards for

Corporate Excellence 2010
In the last edition of Zydan News, we
had reported that our group had been
declared the ‘Emerging Company
of the Year’ by the Economic Times
Awards for Corporate Excellence
2010.
A grand award ceremony was held
at Hotel Trident Oberoi, Mumbai on
8th January 2011 with the who’s who
from India Inc. attending the function.
Our Chairman and Managing Director,
Mr. Pankaj R. Patel is seen here
receiving the award from Environment
Minister, Mr. Jairam Ramesh.

As we take our next step beyond the billion, our Teams BU 1, 2,3 and 4 got together to plan the budgets for the year ahead.
We bring you glimpses of the Budget Meets of our marketing BUs and divisions.
4
 5
On the international beat - a whistle-stop tour of Europe, US, Japan, Brazil, Africa and South East Asia

A salute to the resilient spirit of Team Japan

In February this year, Japan was rocked by a massive earthquake
followed by a washout by the Tsunami waves. The conditions
were grim as there was widespread destruction and radiation
fears loomed large.
Despite these odds, team Zydus Japan has achieved its targets
and has been a key contributor to the Healthy Billion target. The
resilient spirit of the team has really proved that if you have the
will and commitment ‘Nothing is impossible’. We salute this
spirit and express our solidarity to these brave people.

News from Brazil

Our Dy. Managing Director, Dr. Sharvil P. Patel

visits our Brazil office
In December 2010, Our Dy. Managing Director,
Dr. Sharvil P. Patel visited our offices at Brazil. During
his trip he inaugurated the Biologics Department at
our office at Nikkho, Brazil. He is seen here at the
inauguration alongwith Mr. Ashok Bhatia, President
BU ROW and Mr. Amit Dave, Chief Executive Officer,
Zydus Brasil Ltda. and other team members at Brazil.

The learning curve

Various training programmes were organised
for our team at Brazil. For the teams working
on Quality Control and Quality Assurance,
training programmes on specific technical
documentation, following standard operating
procedures and GMPs were organised. Other
training programmes include Practice - a cyclic
training session, RDC17 - Dynamic Training,
and training on regulatory procedures and
GMPs.

Strengthening partnership ties A new beginning at Rio de Janeiro Connecting with customers
There have been
various intiatives
undertaken by the
field force in Brazil
to improve customer
connect and market
reach. Our field
representative, Luis
Felipe Sampaio is
seen here with Dr. Fernando Figueiredo and
field representative,
On the completion of 5 successful years Our new warehouse located at Rio de Janeiro was Sergio Rodrigo
of sales partnership with the distributors, inaugurated by Dra Larissa from the ANVISA is seen posing
Navarro from São Paulo which is our best inspection team on 24 January 2011.
th
with pharmacist
performing distributor in Brazil, a plaque Dra. Jenifer Leite
of appreciation was presented to the owner at a pharmacy on
of Navarro, Mr Marcelo Navarro. Seen Pharmacist Day.
here are Mr. Amit Dave, Elizabeth Prado,
Sales Supervisor and Silvio Reis alongwith
Mr. Navarro and his team.
6
Inauguration of our new office at Mexico

The office of our new subsidiary in Mexico, Zydus Pharmaceuticals Mexico S.A.de C.V was inaugurated by our Dy. Managing Director,
Dr. Sharvil P. Patel. He is seen here alongwith our Executive Director and COO, Mr. Ganesh Nayak, Mr. Bernardo Frisbie, General Manager,
Zydus Pharmaceuticals Mexico, Mr. Prashant Desai, Vice President - Operations, Zydus USA and the team at Zydus Mexico.

Seminar on the India-China Cooperation in the Pharmaceutical Sector in Beijing

The Embassy of India, Beijing alongwith the Federation of Indian Chamber of Commerce and Industry (FICCI), the Indian Drug Manufacturers
Association (IDMA) and the China Chamber of Commerce for Health and Medical Products Import and Export (CCCMHPIE) had organized
a seminar on the ‘India-China Cooperation in the Pharmaceutical Sector’ at Beijing on 15th March 2011.
The objective of the seminar was to provide a platform for key stakeholders of the Indian and Chinese
pharmaceutical industry to discuss and share insights on the recent trends and advances in the
pharmaceutical sector and also look at the growth opportunities in the emerging markets by leveraging
the strengths of both these countries. The emerging markets are poised to be a major growth driver in
the global pharma market by 2015.
Mr. Ashok Bhatia, President, BU ROW presented his views on the ‘Value Proposition of the Indian
Pharmaceutical Sector to China’ at the seminar.

Launch of Amolodipine in Spain

Our group has successfully launched Amolodipine in the Spanish market
through our wholly owned subsidiary, Laborotorios Combix, Spain. After the
acquisition of Combix in 2008, Amolodipine which has been developed at our
Pharmaceutical Technology Centre and manufactured at our manufacturing
unit at Moraiya, is the first Zydus product to be launched by the company.

Our representative at Zydus Spain rep, Ada, selling amlodipine at one

of the pharmacies.
 7
Activities at Myanmar
57th MMA 2011, Yangon

The Zydus team at Myanmar participated at the 57th Annual Conference of the Myanmar Medical Association (MMA) held at Yangon in
January 2011. Zydus’ stall, located at a very strategic location, was quite attractive with well decorated counters, product displays, banners and
literatures to showcase our key products. The entrance of the conference which was inaugurated by the President of Myanmar was sponsored
by our group.
As part of the conference, two symposia were organised by our team, one on ‘Health Challenges in the new millennium with a focus on
cardiology, diabetology and hepatology’ and the other on ‘FAQs in Acute Pain Management’. The first symposium had three eminent speakers
and  KOLs leading the discussions on the topic and more than 400 doctors participated in the symposium. The second one, focused on acute
pain management was chaired by Prof. Kyaw Myint Naing, an Orthosurgeon and President of MMA and the Myanmar Medical council
and the key speaker for the meet was Prof. Myint Thaung, Head Orthosurgeon, University of Medicine. The key brands showcased at the
conference were Nucoxia and Eurovit. Our team also hosted the Presidential lunch at the conference. More than 1500 doctors from across the
country participated at the conference. Our team also participated in similar MMA conferences held at Mandalay, Magwe and Monywa in
Myanmar.

The Zydus brand crossword makes a mark at the orthopaedic A workshop on brand building
conference at Myanmar

Our team at Myanmar also participated in the two day conference of
the orthopaedic society held on 10th and 11th December at Yangon.
Our team from Zydus was dressed in T-shirts bearing the name of
our brand, Aldren. More than 160 doctors visited our stall. The main
attraction of the Zydus stall was the Zydus Crossword which had
clues on the leading brands of our group.
Our group currently ranks 6th in the pharmaceutical market of
Myanmar. Sprucing up our efforts in marketing and brand building
in this market, a brand building workshop was organised for our team
at Myanmar on 17th and 18th March 2011. The workshop focussed
on improving communication skills and how to convey the brand
message strongly and effectively.

Zydus Hospira declared the Lowest Risk site

The Zydus Hospira facility located at Pharmez,
Ahmedabad, has been rated as the ‘Lowest Risk’ site
by the Hospira Corporate Audit team. This is based
on the audit of all the facilities of Hospira across the
world. We congratulate Team Zydus Hospira on this
achievement.
8
Made in India, Launched in Japan – Amolodipine launched in Japan

Our group has successfully launched Amlodipine in Japan

through our subsidiary Zydus Pharma Japan. We are the
first Indian company to launch a product manufactured in
India in Japan. The team also launched Rabeprazole and
Glimeperide in Japan, both of which were Day 1 launches.
With these launches the team is well on its way to achieve its
goal of launching 10 new products each year, over the next 5
years and achieving sales of 10 Billion Yen by 2014 and 20
Billion Yen by 2018.

Doctors’ day out on the Golf Course in South Africa Our team launches Mel OD in Thailand

The year 2011 began on a high note for our team at Thailand with
the launch of the NSAID- Meloxicam (Mel OD) 7.5 mg and 15 mg in
January. The bioequivalence study for this NSAID was successfully
Mr. Tyrone Kundan, our Medical Representative in South Africa
conducted in one of the Government CROs , which gives us an edge
organised an interesting activity for leading doctors and pharmacists
in gaining quick access to the big Medical University Hospitals, in
in South Africa. Doctors tried a hand at the game of golf and
addition to the small hospitals. The field force has already started
thouroughly enjoyed it. The initiative was highly appreciated by the
promoting the product in the market. Our group is the leader in the
doctors and pharmacists.
Omeprazole injections and Nifedipine segments and plans to target
Educating people on diabetes management in Sudan and various other therapeutic segments in this $3bn market.
Uganda
Our team participates
On 14th November 2010 which is the World Diabetes Day, our team at the Thai Rheumatism
at Sudan had organized a diabetes detection and education camp Association (TRA)
at Khartoum, Sudan. Promoting our brand Sugarfree at the camp, exhibition held at Hua Hin
the participants at the camp were offered karakade, the traditional from 19th-20th March 2011.
drink of Sudan which is made out of dry leaves of hibiscus and were
encouraged to use Sugar Free instead of sugar. The Governor of
Khartoum also attended the camp and savoured the drink.
Team Thailand participates at the 10th GI Live Endoscopy
Demonstration
Growing at a rapid pace, Ocid
IV has become the leading
brand in the Gastrointestinal
(GI) segment in the
pharmaceutical industry of
Thailand. To further
strengthen our position in
this key market, our team
at Thailand participated at
At Uganda, the Chairman of the Uganda Diabetes Association,
the ‘10th GI Live Endoscopy Demonstration - Unique Scenarios of
Professor Marcel Andrew Otim addressed the participants of the
Advanced Endoscopy’ conference held at the Queen Sirikit National
medical camp on the importance of managing diabetes. Leading
Convention Center in Bangkok on 16th February 2011. This gave the
physicians from across Uganda also participated in the camp.
team an opportunity to interact with key GI specialists from across
Strengthening the Sugar Free market in Uganda, Zydus Uganda
Thailand. More than 100 doctors visited the Zydus stall represented
recently introduced the 330’s pack and Sugarfree sachets in addition
by Dr. Somchai (Siriraj H.), Dr. Varosha (Chulalongkorn), Dr. Tanissa
to the 110’s pack, 360’s pack and 100 gms powder which are currently
(Police H.), Dr. Udom (Siriraj H.).
marketed in Uganda.
 9
Reaching out in times of crisis

Zydus Pharmaceuticals USA Inc. has been partenering with the Americares
Foundation to reach out with medical supplies and aid to people in crisis
around the world.
The escalating violence and political conflict in Libya has forced thousands
of people out of Libya and also disrupted basic services and supply lines
within the country. Thousands of internally displaced people increasingly
lacked access to medical care and lifesaving medicines. In such a situation,
Americares stepped up its efforts in reaching the critically needed medical
aid including surgical supplies, burn and wound care, cardiovascular and
diabetic medicines as well as pain relievers, antibiotics, antiseptics and
anesthetics.
Americares in association with Zydus USA has also been instrumental in
providing medical aid to the vulnerable communities in the Dominican
Republic, including the earthquake victims in Haiti.

Team Vietnam organises the Bonmax Workshop for doctors

To tap the Women’s Healthcare segment in Vietnam, a CME
was conducted on 19th February 2011 for the doctors on Bonmax
(Raloxifene), our leading brand used in the treatment and prevention
of osteoporosis in menopausal women. The speakers at the workshop
included Prof. Thit Lwin, HOD, Traumatology department, Yangon
Hospital, Myanmar, Prof. Nguyen Duy Tai, HOD, Obstetrics/
Gynaecology , HCMC Medical University, Vietnam and Prof. Tran
Van Thiep, HOD , Oncology, HCMC Medical University, Vietnam.
They provided insights on the product and hands on training on the
usage of Raloxifene. The participants in this educative workshop
included department heads, key opinion leaders, Vice Directors
and Directors from leading gynaecology hospitals.

Zydus France says Namaste at Pharmagora, Paris

Zydus France participated at the Pharmagora show held

at Paris from 26th to 28th March 2011. Pharmagora, which
brings together pharma professionals from across Europe on
a common platform, is one of the most prestigious pharma
conferences in the region. Zydus’ stall was very chic with
an Indian look and feel as the respresentatives at the stall
were dressed in the Indian attire. The conference provided
an opportunity for our team to interact with key stakeholders
from the pharma industry in Europe.

Our Chairman and Managing Director awarded a

Special Recognition Award by IPA
In recognition of his ongoing contributions to the growth of
the Pharmaceutical Industry, Research and the Profession
of Pharmacy, our Chairman and Managing Director,
Mr. Pankaj R. Patel was awarded a Special Recognition Award
2010 by the Indian Pharmaceutical Association (IPA).
The glittering function was attended by the industry
stalwarts, representatives from regulatory bodies, educators
and healthcare professionals and representatives of national
and international affiliating organisations.
10

Our 28th Quarterly forum strikes the right chord

In April this year, Zydans converged for the 28th Quarterly forum. The occasion was an apt
one as it was held immediately after we achieved our goal of the Healthy Billion - clocking
sales of over $ 1 billion by 2015 . Interestingly, it was not the customary bugle that led the
proceedings, but the striking of the gong that reverberated at the meet as each team took
the stage.
 11

Our Chairman and Managing

Director, Mr. Pankaj R. Patel
gave a special memento to all the
participants, a replica of the ‘Midas
Touch’, the cover story on our group in
Business India.
As we take our next step beyond the billion, all participants flashed
badges of the new mascot ‘Beyond the Billion’.

During the Quarterly meet in April, the winners of the last leg of the Zydus HB League (Q4) were declared. It was was an exciting affair as
there were several contenders for the top honours. Here’s what the scorecard had to say...

Winner’s Gallery : Q4

The winners of Q4 for the Best All Round Performance amongst the revenue generators were Team USA with Team Liva in the 1st runner’s
up position and Team Evona in the 2nd runner’s up position.

Amongst the non-revenue generators Team Manufacturing emerged the winners with Team GDSO in the second place. The Chairman’s
Special Award went to Team Japan.
12

Stepping Beyond the Billion - Onsite Strategic Business Review Meets

Starting from April 2011, a new management governance system has been introduced. Instead of the quarterly meets in which
Zydans from across the group would converge, these meetings will be structured and conducted, differently. There would be annual
discussions on plans which will set objectives. There will be meetings for organizational development, periodic on-site business
reviews and a bi-annual strategic meetings which will look at the larger perspective of our operations.
The first round of on-site business reviews were held across the group in April and May with Teams at USA, France, Japan, Emerging
Markets and India. Members of the top management are seen posing with the teams in USA and Brazil during the tour.

Our India operations – about Centurions, Brand Power, Top Scorers and New Initiatives

Aten scores a century

The Healthy Billion year ended on a high note for team Aten as the brand’s sales crossed the
Rs. 100 crore mark during the year. With this Aten becomes the first brand of our group to achieve
this milestone. From a turnover of Rs. 38 crores in 2002 Aten has grown to become a centurion
brand and is currently the leader in the anti-hypertensive segment.

Liva riding on the wave of performance

For team Liva the theme for 2010 – 11 was the ‘Wave’ which was the
driving force for the team’s excellent performance during the year. Liva
has been on target for more than 8 consecutive quarters. Liva currently
ranks amonst the top 10 derma companies in India. With sales crossing
2.5 lac units, Liva’s lead brand Skinlite is currently the leader in the
depigmentation segment. (IMS MAT Feb 2011)
Consolidating its position in the derma market, team Liva recently
launched the Danclear gel, an anti-dandruff gel. Strengthening its
position with the expansion of its exisiting product portfolio and the [Ketoconazole 2% + ZPTO 1%]

launch of new products in newer segments, Team Liva is well on its way Stays Longer, Works Better
to rank amongst the top 5 derma companies in India.

Cintodac - one of the leaders in the gastrointestinal segment

The lead brands of Corza, Cintodac, a novel combination of Pantodac 40 (the No.1
original PPI brand in India) and Cintapro-OD launched last year have been growing at a
rapid pace.
From a sales of Rs. 80 lacs in the first month of launch in May 2010, Cintodac is expected
to clock sales of Rs. 6 crores in the first year of its launch. Riding on an overwhelming
response, Cintodac is rated as one of the best new launches for our group in the
gastrointestinal segment.